It has been shown that increased TK1 mRNA levels in the plasma-derived sEVs are also associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients [49], which agrees with our data, and strengthen the plausibility of TK1 as a reliable tool for determining tumor progression. Here, CDK4 is linked to neoplasm.